Table 1. Baseline Characteristics of the Study Participants.
| Variables | HM Cohort n = 281 | HV Cohort n = 204 | ||||||
| LAA = 78 | SAD = 97 | CE = 106 | p | LAA = 59 | SAD = 56 | CE = 89 | p | |
| Age (mean, SD) | 70.5 (9.6) | 68.6 (10.4) | 75.8 (8.7) | <0.001 | 69.3 (11.8) | 69.8 (11.6) | 75 (14.4) | <0.001 |
| Sex, female | 23 (29.3%) | 29 (29.9) | 62 (58.5) | <0.001 | 21 (35.6) | 23 (41.1) | 53 (59.6) | 0.009 |
| Diabetes Mellitus | 34 (43.6%) | 33 (34) | 37 (34.9) | 0.36 | 19 (32.2) | 18 (32.7) | 25 (28.1) | 0.8 |
| Hyperlipidemia | 46 (59%) | 37 (38.1) | 45 (42.5) | 0.016 | 15 (25.4) | 16 (29.1) | 21 (23.6) | 0.76 |
| Hypertension | 52 (66.7%) | 65 (67%) | 82 (77.4) | 0.17 | 35 (59.3) | 27 (49.1) | 51 (57.3) | 0.50 |
| Current smoking | 29 (37.7%) | 27 (28.1%) | 11 (10.6) | <0.001 | 12 (20.3) | 10 (18.2) | 12 (13.5) | 0.52 |
| Coronary disease | 13 (17.8) | 7 (7.7) | 20 (19.8%) | 0.05 | 0 | 0 | 8 (9) | 0.005 |
| Atrial fibrillation | 0 | 0 | 92 (87%) | <0.001 | 0 | 0 | 45 (51%) | <0.001 |
| Methylation % | 74 | 74.6 | 74.2 | 0.68 | 76.4 | 77 | 77.4 | 0.12 |
| (median, IQR) | (71.8–75.9) | (71.8–76.4) | (71.7–76.2) | (75.5–77.6) | (75.2–77.9) | (76.3–77.9) | ||
| Methylation (n, quartiles) | 80.2–75.9 (19, 24.4%) | 30 (30.9%) | 31 (29.2%) | 0.91 | 81.3–77.6 (15, 25.4%) | 19 (36%) | 32 (36%) | 0.102 |
| 75.9–73.9 (20, 25.6%) | 26 (26.8%) | 26 (24.5%) | 77.6–76.4 (15, 25.4%) | 15 (26.8%) | 30 (33.7%) | |||
| 73.9–71.7 (20, 25.6%) | 17 (17.5%) | 23 (21.7%) | 76.4–75.5 (15, 25.4%) | 5 (8.9%) | 12 (13.5%) | |||
| 71.7–65.5 (19, 24.4%) | 97 (24.7%) | 26 (24.5%) | 75.5–68.6 (14, 23.7%) | 17 (30.4%) | 15 (16.9%) | |||
Univariate analysis of LUMA methylation as continuous variable and quartile categories. Ischemic stroke (IS), large-artery atherosclerosis (LAA), small-artery disease (SAD), and cardio-aortic embolism (CE), in HM Cohort and HV Cohort. LAA was taken as reference in methylation quartiles.